{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.3","upperLimit":"43.8","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Survival is assessed as time to death from first day of treatment The OS function for response-evaluable will be estimated using the product-limit (Kaplan-Meier) estimator, along with 95% confidence bounds. The median survival will be estimated from the survival function. The analysis will be repeated on all patients who receive any therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with AL will receive Bendamustine and Dexamethasone\n\nBendamustine: Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:\n\n* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle\n* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle\n\nAvailable to qualifying subjects is the option to dose escalate to dose level (+)1:\n\n* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)\n* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)\n\nDexamethasone: 40 mg orally on days 1, 8, 15, 22 of each cycle","id":"OG000","title":"Treatment Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}